Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1

Low‐dose imatinib with monitoring of drug concentrations in blood may successfully control Philadelphia chromosome‐positive mixed phenotype acute leukemia (Ph+MPAL), particularly in elderly patients with comorbidities.

Detalles Bibliográficos
Autores principales: Okayama, Yusuke, Takakuwa, Teruhito, Otomaru, Ippei, Horiuchi, Mirei, Miura, Akiko, Araki, Taku, Fujitani, Yotaro, Yamamura, Ryosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123726/
https://www.ncbi.nlm.nih.gov/pubmed/34026165
http://dx.doi.org/10.1002/ccr3.4126
_version_ 1783692989963436032
author Okayama, Yusuke
Takakuwa, Teruhito
Otomaru, Ippei
Horiuchi, Mirei
Miura, Akiko
Araki, Taku
Fujitani, Yotaro
Yamamura, Ryosuke
author_facet Okayama, Yusuke
Takakuwa, Teruhito
Otomaru, Ippei
Horiuchi, Mirei
Miura, Akiko
Araki, Taku
Fujitani, Yotaro
Yamamura, Ryosuke
author_sort Okayama, Yusuke
collection PubMed
description Low‐dose imatinib with monitoring of drug concentrations in blood may successfully control Philadelphia chromosome‐positive mixed phenotype acute leukemia (Ph+MPAL), particularly in elderly patients with comorbidities.
format Online
Article
Text
id pubmed-8123726
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81237262021-05-21 Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1 Okayama, Yusuke Takakuwa, Teruhito Otomaru, Ippei Horiuchi, Mirei Miura, Akiko Araki, Taku Fujitani, Yotaro Yamamura, Ryosuke Clin Case Rep Case Reports Low‐dose imatinib with monitoring of drug concentrations in blood may successfully control Philadelphia chromosome‐positive mixed phenotype acute leukemia (Ph+MPAL), particularly in elderly patients with comorbidities. John Wiley and Sons Inc. 2021-05-05 /pmc/articles/PMC8123726/ /pubmed/34026165 http://dx.doi.org/10.1002/ccr3.4126 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Okayama, Yusuke
Takakuwa, Teruhito
Otomaru, Ippei
Horiuchi, Mirei
Miura, Akiko
Araki, Taku
Fujitani, Yotaro
Yamamura, Ryosuke
Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1
title Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1
title_full Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1
title_fullStr Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1
title_full_unstemmed Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1
title_short Efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);BCR‐ABL1
title_sort efficacy and safety of low‐dose imatinib in an elderly patient with mixed phenotype acute leukemia with t(9;22)(q34;q11.2);bcr‐abl1
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123726/
https://www.ncbi.nlm.nih.gov/pubmed/34026165
http://dx.doi.org/10.1002/ccr3.4126
work_keys_str_mv AT okayamayusuke efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT takakuwateruhito efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT otomaruippei efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT horiuchimirei efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT miuraakiko efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT arakitaku efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT fujitaniyotaro efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1
AT yamamuraryosuke efficacyandsafetyoflowdoseimatinibinanelderlypatientwithmixedphenotypeacuteleukemiawitht922q34q112bcrabl1

Ejemplares similares